- Details
- Petros Grivas, MD Ph.D. and Alicia Morgans discuss the rapidly changing landscape in the treatment of advanced urothelial cancer. Dr. Grivas discusses the era of immunotherapy in advanced bladder cancer and the development of new drugs, new combinations, and biomarkers. Biographies: Petros Grivas, MD, Ph.D. is an Associate Professor and the Clinical Director of the Genitourinary Cancers Program at...
|
- Details
- Wassim Kassouf and Alicia Morgans discuss the role of neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) including the accuracy of clinical staging and treatments. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a Professor in the Division of Urology and Vice-Chair of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and ren...
|
- Details
- Despite the fact that most patients do well with a radical cystectomy, the procedure is physiologically challenging and is associated with real morbidity, including hospitalizations, risk of re-operation, long-term sequelae and post-operative mortality. Jason Efstathiou, MD discusses the progress in trimodality therapy with the combination of surgery, chemotherapy, and radiation. Trimodality thera...
|
- Details
- Andrea Necchi and Alicia Morgans discuss the evolution of neoadjuvant treatment for muscle-invasive bladder cancer (MIBC) including the role of immunotherapy and chemotherapy prior to radical surgery. They discuss the PURE-01study which included all-comers regardless of cisplatin eligibility. The early data from PURE-01 with neoadjuvant pembrolizumab demonstrated a 42% pathological complete respon...
|
- Details
- Scott Tagawa discusses his recent research on the use of antibody-drug conjugate (ADC) sacituzumab govitecan in advanced metastatic urothelial carcinoma. The primary endpoint of the study was the objective response rate and the results of the Phase 2 subset were presented at ASCO GU 2019. The responses were seen with reasonable drug tolerance, a manageable and predictable safety profile, and a rel...
|
- Details
- Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. T he SWOG 1806 study , Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle...
|
- Details
- Matthew Galsky and Alicia Morgans share in a discussion on combination and maintenance strategies for muscle-invasive and metastatic bladder cancer and a number of reasons for combining immunotherapy with immune checkpoint blockade. These reasons include the concept of immunogenic cell death, depletion of suppressive immune cell subsets and independent drug action. Biographies: Matthew Galsky, MD,...
|
- Details
- Alicia Morgans interviews Andrea Apolo who details the trial design and current status of the Phase III adjuvant AMBASSADOR trial for patients with high-risk muscle-invasive bladder cancer (MIBC) and the need to develop additional treatment options for patients who are resistant to chemotherapy and develop recurrent disease. The AMBASSADOR trial aims to answer the question if there is a benefit to...
|
- Details
- (Length of Discussion: 12 min) A conversation between Petros Grivas and Alicia Morgans where they discuss the trials in the neoadjuvant, adjuvant and perioperative setting in advanced bladder cancer from ESMO 2018. They talk about the biology of the disease and considerations of available therapies, single vs combination, and for chemotherapy ineligible, as well as patients who opt out of chemothe...
|
- Details
- (Length of interview: 17 min) Cora Sternberg and Alicia Morgans provide a review of immunotherapy advances in both renal cell and bladder cancer. They review past and current trials providing insights into potential clinical and treatment applications. Biographies: Cora Sternberg MD, FACP Clinical Director of the Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Former Chi...
|
